© 2024 HSP News Service, L.L.C.
As reported in the Journal of Clinical Oncology by Laurent et al, expert review of lymphoma diagnoses in French patients resulted in a change in diagnosis in 19.4% of cases of noncutaneous disease. Study Details In the study, 42,145 samples from patients with newly diagnosed or suspected...
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in various types of high-grade, aggressive non-Hodgkin lymphomas (NHLs), including peripheral T-cell lymphomas, central...
As reported in the Journal of Clinical Oncology by Chen et al, the phase II KEYNOTE-087 trial has shown that the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) is highly active in patients with relapsed or refractory classical Hodgkin lymphoma. Findings in the study ...
In an article in the Journal of Clinical Oncology, Sasse et al reported long-term follow-up of German Hodgkin Study Group trials in early-stage favorable and unfavorable Hodgkin lymphoma. The updates cover the HD7 and HD10 trials in favorable disease and the HD8 and HD11 trials in unfavorable...
In the international phase III REMARC trial reported by Thieblemont et al in the Journal of Clinical Oncology, lenalidomide (Revlimid) maintenance was found to prolong progression-free survival vs placebo in older patients with diffuse large B-cell lymphoma responding to first-line R-CHOP...
Alexandra Levine, MD, MACP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, California, and has been on the front lines of the AIDS epidemic from the beginning—before the disease even had a name. Dr. Levine spoke with The ASCO Post about ...
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
The final results of the European phase III International Extranodal Lymphoma Study Group (IELSG)-19 trial, reported in the Journal of Clinical Oncology by Zucca et al, showed that event-free and progression-free survival were better with rituximab (Rituxan) plus chlorambucil vs either agent alone...
Final results of the phase III EORTC/LYSA/FIL H10 trial confirm the benefits of early positron-emission tomography (PET)-adapted treatment in patients with stage I or II Hodgkin lymphoma. The results were reported by André et al in the Journal of Clinical Oncology. Study Details The...
As reported by Kochenderfer et al in the Journal of Clinical Oncology, remission in patients with advanced lymphoma induced by treatment with chimeric antigen receptor (CAR) T cells targeting CD19 (CAR-19) is associated with elevated serum interleukin-15 (IL-15) levels. Study Details The study...
Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.
Christian Taverna, MD, a lymphoma specialist at the Hospital Münsterlingen in Switzerland, commented on this patient series for The ASCO Post. He noted that the Swiss Group for Clinical Cancer Research (SAKK) tried to address the question of the optimal duration of rituximab (Rituxan) maintenance...
Patients with follicular lymphoma are clearly living longer without disease progression, but what clinician has had no patients progress? Michael Auerbach, MD, a hematologist/oncologist in private practice in Baltimore and Clinical Professor of Medicine at Georgetown University, may have these...
In a study in the Swedish population reported in the Journal of Clinical Oncology, Sud et al found an increased risk of second cancers in survivors of Hodgkin lymphoma. Risk was further augmented in those with first-degree relatives with a cancer diagnosis. Study Details The study used data from...
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the treatment of adult and pediatric patients who have refractory classical Hodgkin lymphoma or have relapsed after three or more prior lines of...
On January 19, ibrutinib (Imbruvica) was granted accelerated approved for treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20–based therapy.1 Supporting Efficacy Data Approval was based on overall response rate in a...
In an analysis of German Hodgkin Study Group trials reported in the Journal of Clinical Oncology, Bröckelmann et al found that the cumulative incidence of late relapse in patients with classical Hodgkin lymphoma was 6.9% at 20 years and that late relapse was more common among those with...
As reported in The Lancet Oncology by Borchmann et al, a phase III German Hodgkin Study Group trial in advanced Hodgkin lymphoma showed no progression-free survival benefit of adding rituximab (Rituxan) in patients with positive positron-emission tomography (PET) findings after two courses (PET-2)...
On January 19, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica) for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti–CD20-based therapy. Accelerated approval was granted for this indication based...
After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms. About one-third of infected teenagers and young adults nevertheless develop infectious mononucleosis, which usually wears off after a few weeks. ...
Technologic advances for detecting and analyzing cell-free circulating tumor DNA (ctDNA) from peripheral blood offer a precision method for monitoring diffuse large B-cell lymphoma (DLBCL). Although most patients with DLBCL are cured with initial therapy, those who are not cured have a poor...
In a study reported in Science Translational Medicine, Florian Scherer, MD, David M. Kurtz, MD (Conquer Cancer Foundation Young Investigator), Aaron M. Newman, PhD, and colleagues from Stanford University found that analysis of circulating tumor DNA (ctDNA) permits identification of patterns of...
Stephen Ansell, MD, PhD, Chair of the Mayo Clinic Lymphoma Group, said the “exciting results” of these studies indicated that “we have come a long way in Hodgkin lymphoma.” “It’s been very gratifying to see that the excellent initial trial results with the anti–programmed cell death protein 1...
Classical Hodgkin lymphoma is one of the malignancies most susceptible to treatment with monoclonal antibodies targeting the programmed cell death protein (PD-1). Nivolumab (Opdivo) has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed/refractory...
The BCL-2 inhibitor venetoclax (Venclexta) was found to be active in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), according to a phase I study reported by Davids et al in the Journal of Clinical Oncology. Further study of this agent, including in combination therapy to augment...
In a Danish population–based study reported in the Journal of Clinical Oncology, Jakobsen et al found that patients with diffuse large B-cell lymphoma (DLBCL) in first remission and event-free at 24 months after treatment have a low loss of residual lifetime compared with the general...
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in follicular lymphoma. For full details of these study abstracts, visit http://www.bloodjournal.org/content/128/22....
Anas Younes, MD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, New York, commented on the brentuximab vedotin (Adcetris)/nivolumab (Opdivo) combination studies, noting that complete response rates of 60% are “impressive.” “It seems that in the pretransplant setting, the...
Response rates of 90% to 100% were achieved in early studies evaluating the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma. The findings were presented at the 2016 American Society of Hematology (ASH) Annual Meeting &...
Chimeric antigen receptor (CAR) T-cell therapy continues to have impressive showings in patients with aggressive hematologic malignancies and no other good treatment options. Interim results of the pivotal phase II ZUMA-1 trial, the first multicenter trial of the experimental CAR T-cell therapy...
The U.S. Food and Drug Administration (FDA) today approved ibrutinib (Imbruvica) for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti–CD20-based therapy. Accelerated approval was granted for this indication based on...
In a study reported in the Journal of Clinical Oncology, Gibson et al found that clonal hematopoiesis of indeterminate potential at the time of autologous stem cell transplantation (ASCT) in patients with lymphoma was associated with an increased risk of poorer outcomes. Study Details In the...
The final results of the international phase III ORCHARD study, reported in the Journal of Clinical Oncology by van Imhoff et al, showed no difference in progression-free survival with the addition of ofatumumab (Arzerra) vs rituximab (Rituxan) to cisplatin, cytarabine, and dexamethasone (O-DHAP vs ...
“This study is important because R-CHOP [rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone] has been the standard of care for many years. CHOP, the chemotherapy backbone, has withstood challenges from more aggressive regimens in the past. The excellent clinical outcomes observed ...
Long-awaited results of the Cancer and Leukemia Group B (CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition. The study failed to show that dose-adjusted EPOCH-R (etoposide,...
Speaking about the GALLIUM study in the ASH News Daily, Brad S. Kahl, MD, of Washington University School of Medicine, St. Louis, commented, “It is a potentially practice-changing study that clearly shows an 8% absolute improvement in progression-free survival at 2 years for the patients getting...
Induction and maintenance therapies with obinutuzumab (Gazyva) were superior to rituximab (Rituxan) induction and maintenance in patients with untreated follicular lymphoma, according to results of the phase III GALLIUM study presented at the Plenary Session during the 58th American Society of...
Positive studies about brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma1 and rituximab (Rituxan) maintenance therapy in mantle cell lymphoma (MCL)2 were reported at the 2016 Annual Meeting of the American Society for Hematology (ASH). “These abstracts each focus on approved agents and...
A combination of two targeted agents has demonstrated safety as well as encouraging signs of effectiveness in a phase I clinical trial in patients with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Davids et al reported the findings at the 58th American ...
Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).
Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).
Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, discusses in French phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).
Immune cellular therapy is a promising new area of cancer treatment. Anticancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and kill cancer cells. Moffitt Cancer Center physician-scientist Fredrick L. Locke, ...
Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Alex F. Herrera, MD, of City of Hope National Medical Center, discuss study findings that suggest allogeneic stem cell transplantation may overcome the chemoresistance of double-hit/double-expressor tumors (Abstract 830).
Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses agents in the pipeline for follicular lymphoma, including drugs targeting the immune microenvironment, novel monoclonal antibodies, and emerging immunotherapeutics.
Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470).
Jonathon Cohen, MD, and Sagar Lonial, MD, both of Emory University, discuss study findings on R-CHOP vs DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma (Abstract 469).
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, for the treatment of patients with refractory classical Hodgkin lymphoma or for...